During the visit, Takeda met with a range of Finnish public and private organisations, including HUS CleverHealth Network, biobanks, register owners, academic research organisations (for example Institute for Molecular Medicine Finland), scientists, as well as cutting-edge startups, not forgetting Health and Social Data Permit Authority Findata and Helsinki Business Hub as well as Health Capital Helsinki.
Takeda, a globally leading biopharma company with 50 000 employees, launched in 2019 its Nordic Center of Excellence for Innovation with a focus on digital health and artificial intelligence and is already partnering actively with several Finnish health tech organisations and companies.
Anne Heatherington, Head of Takeda Global R&D Data Sciences Institute: ”The Finnish health tech innovation ecosystem has embraced the opportunities offered by digital health and artificial intelligence, and that is why Takeda has made sustained effort to build partnerships here. The high quality of Finnish health care, science and technology, and health data, as well as thriving startup scene and overall excitement for innovation makes it an excellent place for Takeda’s efforts to pioneer data driven innovation in health care.”
Silvia Bäckström, Head of Center of Excellence for Innovation Nordics: “The Nordic countries establish together a globally leading environment at the intersection of health, data, and digital and artificial intelligence innovation. This was a key reason for Takeda’s decision to establish last year a Center of Excellence for Innovation with focus on digital and artificial intelligence in the Nordics. Presence and partnering in Helsinki is a crucial part of our expanding innovation efforts in the Nordics.”
Cover photo: Anne Heatherington, Ph.D., Senior Vice President and Head of Data Institute (DSI), Takeda Pharmaceuticals
Photos: Miika Fadjukov/MedEngine